Blood donor deferral: time for change? An evidence-based analysis

Vere Borra¹
Giovani Vandewalle¹
Hans Van Remoortel¹
Veerle Compernolle¹,²
Emmy De Buck¹
Philippe Vandekerckhove¹,³

¹Belgian Red Cross-Flanders, Mechelen, ²Faculty of Medicine, University of Ghent, Ghent, ³Department of Public Health and Primary Care, Faculty of Medicine, KU Leuven, Leuven, Belgium

Abstract: Donor selection remains an important part in the safety of the blood supply all over the world. Yet, donor deferral criteria seem to be strongly based on the precautionary principle protecting safety and quality, and on supply and expense considerations. This review therefore provides an overview of the available evidence on donor exclusion criteria, as well as on their cost-effectiveness, for the most frequent reasons of donor deferral in our region. PubMed was queried to retrieve primary research studies, systematic reviews, and health technology assessments (HTAs) concerning donor exclusion criteria. With a similar approach, HTAs about the different blood-banking safety interventions were included. Reasons for donor deferral were recorded via the blood bank information system of the Belgian Red Cross-Flanders. Seven systematic reviews were identified: four on donor safety (hypotension, hypertension/type 2 diabetes, epilepsy, and higher age) and three on recipient safety (hemochromatosis, men who have sex with men, and endoscopy). Forty-three low-quality observational studies were included, as well as 16 HTAs: three about donor exclusion criteria and 13 cost-utility analyses about blood-banking safety interventions. In general, the available evidence for deferral reasons was of low quality, and for 60% of the top 30 reasons for excluding donors, no evidence was found. Blood banking shows its unique position as many safety measures far exceed the normally accepted cost of €50,000/quality-adjusted life-years. The historical model based on the precautionary principle and on supply and expense considerations provides adequate supplies of safe blood at a reasonable price. More and better primary research and evidence-based analyses are required, however, before this model can be replaced by an evidence-based approach. Meanwhile, policy makers should provide guidance at the level of principles, not at the level of technical measures, about the balance between patient and donor rights, and about the acceptable cost-effectiveness implications of these choices.

Keywords: blood donation, deferral criteria, evidence-based, health technology assessment

Introduction

Patients in need of blood products are entitled to an adequate supply of safe blood at an acceptable price.¹ It is the balanced combination of supply, safety/quality, and cost considerations that explains how donor deferral historically developed in the blood-banking sector. Blood donor deferral measures form an essential part of this paradigm since they are effective, cheap, and can be implemented rapidly in case of emerging threats (eg, HIV in the 1980s, West Nile Virus, amongst others). Blood donors can be deferred for reasons of donor or patient safety, product quality, or feasibility of the collection (Table 1).²
Exclusion criteria, for instance, could be more relevantly acceptable price. This implies that donor selection criteria quantities of safe blood but also expect to receive it at an acceptable price. This implies that donor selection criteria should be cheap and easy to apply during blood drives. Age practical and economic arguments come into play: how difficult and costly would it be to reliably differentiate individual elements come into play. It is a criticism often heard for exclusion based on age, men who had sex with men (MSM), etc: not everybody in a group is less likely to be excluded than smaller groups. To illustrate this latter point, because of the variant Creutzfeldt–Jakob Disease threat, in most of continental Europe, potential donors within a particular population?

Furthermore, there is little consideration for preferences or sensitivities on the donor side: groups of donors are readily excluded if the average infectious risk for those groups is higher than the overall average in the population, with exceptions made only if the exclusion measure threatens the overall blood supply, which is considered in the second pillar of the model. Indeed, it is only in extreme circumstances that exceptions have been considered: the UK, for instance, due to the bovine spongiform encephalopathy epidemic, decided to destroy all plasma derived from whole-blood donations within the UK, and started importing plasma from countries with a low risk of the variant Creutzfeldt–Jakob Disease. Taking into account the impact on supply to define the level of exclusion is a form of irrationality, as it implies that a very large group is less likely to be excluded than smaller groups. To illustrate this latter point, because of the variant Creutzfeldt–Jakob Disease threat, in most of continental Europe, potential blood donors who resided for >6 months in the UK in the period 1980–1996 are permanently excluded. If the UK used a similar approach, it would find itself without blood donors overnight. The US, on the other hand, goes a step further and even excludes donors who have spent a cumulative time of ≥5 years in any combination of European countries since 1980. If European countries used a similar approach, they would find themselves without blood donors overnight.

In addition, and only secondary to supply considerations (and therefore groups as a whole), individual elements come into play. It is a criticism often heard for exclusion based on age, men who had sex with men (MSM), etc: not everybody in a group has the same risk or displays the same risk behavior. However relevant the differences between subgroups may be, practical and economic arguments come into play: how difficult and costly would it be to reliably differentiate individual donors within a particular population?

This brings us to the third pillar of the model: expense considerations. People not only expect to receive adequate quantities of safe blood but also expect to receive it at an acceptable price. This implies that donor selection criteria should be cheap and easy to apply during blood drives. Age exclusion criteria, for instance, could be more relevantly

### Table 1 Seven categories of donor deferral criteria

| Category | Description |
|----------|-------------|
| I: | Conditions that may increase the risk of a serious adverse donor reaction |
| II: | Conditions that may interfere with the feasibility of the collection |
| III: | Conditions that may affect the quality of the blood products |
| IV–VII: | Conditions that may increase the risk of a serious donor-related transfusion reaction |

**Abbreviations:** TTI, transfusion-transmissible infection; TSE, transmissible spongiform encephalopathy.
based on biological rather than chronological age, but this would drive the cost up dramatically.

In summary, it is the combination of the precautionary principle and the potential impact on the blood supply and on cost which has defined donor exclusion criteria up till now, and even when considering donor preference, economic and practical considerations were taken into account. Altogether, this resulted in comprehensive donor selection guidelines based on national legislation to which almost invariably requirements of other sources were added (such as National Haemovigilance Networks, professional advisory bodies or initiatives based on local regional epidemiological risks, and perceptions of best practice or simply custom and practice).

Alternatives to the precautionary principle exist but always make the decision-making process more complex, and hence require more and more robust scientific data. We therefore decided to apply the relatively new and powerful tool of evidence-based medicine and searched for the available evidence in the scientific literature underpinning the most common exclusion criteria. In addition, we also identified the available health technology assessments (HTAs) on safety measures in blood banking.

The aim of this paper is to provide an overview of (1) the available evidence base for donor exclusion criteria applied to the most common reasons of deferral in our region, and (2) the corresponding health economic data with regard to donor exclusion criteria, and health economic data with regard to blood-banking safety measures in general.

**Methods**

**Systematic literature search for systematic reviews, primary studies and HTAs on blood donor selection criteria**

We searched MEDLINE (using the PubMed interface) for available relevant systematic reviews concerning blood donor selection criteria with the search strategy available in [Supplementary materials](#). Next, we searched for primary research studies using the search strategy in [Supplementary materials](#). In addition, we searched for HTAs in MEDLINE (using the PubMed interface) and the Centre for Reviews and Dissemination database, using the search strategies in [Supplementary materials](#).

All available systematic reviews concerning blood donor selection criteria were included.

The following in- and exclusion criteria for the selection of primary research articles were used. For the outcome “infection”, we included blood donors (or people eligible to give blood) living in areas most relevant for our Blood Service: Northern, Western, and Southern Europe (Albania, Andorra, Austria, Belgium, Bosnia and Herzegovina, Croatia, Denmark, Estonia, Finland, France, Germany, Gibraltar, Greece, Iceland, Italy, Ireland, Kosovo, Latvia, Liechtenstein, Lithuania, Luxembourg, Macedonia, Malta, Monaco, Montenegro, the Netherlands, Norway, Portugal, San Marino, Serbia, Slovenia, Spain, Sweden, Switzerland, Vatican City), the USA, Canada, Australia, and New Zealand. For the outcome “donor adverse events”, no geographic limitations were used. The population containing blood donors, but not exclusively blood donors, was excluded.

Risk factors included were risk factors for possible transfusion-transmissible infections or adverse events for the donor.

Outcomes included were related to possible (exposure to) infections or adverse events.

Intervention studies (randomized controlled trials, controlled clinical trials, before-and-after studies) and observational studies (case–control studies with cases either having a diagnosed infection or showing adverse events and a control group without infections of adverse events) were included. Studies had to give an indication of significance (by mentioning a P-value, a confidence interval, or in a narrative way). Non-controlled studies, case reports, case series, letters, comments, opinion pieces, narrative reviews, modeling studies, or studies that fail to mention levels of significance were excluded.

The following in- and exclusion criteria for HTAs were used. Blood donors (who were deferred) from developed and/or developing countries were included. Risk factors for possible TTIs or adverse events for the donor were included. Both costs and effects (life-years gained or disease-specific outcomes as reported in cost-effectiveness studies, quality-adjusted life-years [QALY] as reported in cost-utility studies) or a health gain expressed in monetary units (as reported in cost-benefit analyses) were included as outcomes. Cost-effectiveness analyses, cost-utility analyses, and/or cost-benefit analyses were included. Studies that only reported information on costs or health effects were excluded. Only studies in English were included.

**Systematic literature search for HTA on all blood banking safety measures**

In order to determine the cost/QALY for current blood bank safety measures, we searched the literature for existing HTA, using the search strategies in [Supplementary materials](#). The following inclusion and exclusion criteria for cost-utility analyses were used. Blood donors from developed countries were included. Studies performed in Belgium/the Netherlands were preferably included; if not present, other settings (developed countries) were selected. Blood donors
from developing countries were excluded. Medical health questionnaire, screening lab tests (ie, nucleic acid test for hepatitis C virus [HCV]/hepatitis B virus [HBV]/HIV, tests for bacteria), screening tests regarding component preparation (Intercept Blood System for platelets, pathogen inactivation), and screening tests regarding utilization (hemovigilance) were included. Screening tests for other viruses (eg, West Nile virus) were excluded. We included studies with no intervention or another screening test as a comparator. Cost/QALY was the outcome. Cost-utility analyses were included. Only studies in English were included.

Analysis of the most frequent reasons for donor exclusion
Donor deferrals are accurately recorded in the blood bank information system of the Belgian Red Cross-Flanders by using unique deferral codes. To monitor changes in donor selection, a trend analysis is performed on a regular basis by ranking deferral codes according to their frequency.

Results
Evidence that supports donor selection criteria
Table 2 gives an overview of the number of systematic reviews, primary research studies, or HTAs containing evidence that (does not) supports blood donor selection criteria.

Systematic reviews
Our search for relevant systematic reviews concerning blood donor selection criteria identified (1) two published and two unpublished reviews concerning deferral criteria aimed at donor safety, and (2) two published and one unpublished review concerning selection criteria aimed at recipient safety (Table 2).

Concerning the safety of the blood donor, one systematic review investigated the effect of pre-donation hypotension on whole-blood donor adverse reactions. The available evidence showed that hypotensive blood donors do not have a greater risk for adverse donor reactions, compared with normotensive blood donors. The overall quality of the ten included observational studies was limited and rated “low” according to the Grading of Recommendation, Assessment, Development, and Evaluation methodology.

Another systematic review was published on the safety of blood donation from individuals with treated hypertension or diabetes, was predictive of increased adverse reactions in blood donors, but the level of overall evidence was limited.

Recently, a systematic review was performed on whole-blood donation by epilepsy patients. Based on three observational studies, no significant association could be demonstrated between a history of epilepsy and complaints during or after blood donation (personal communication Centre for Evidence-Based Practice, Belgian Red Cross-Flanders, 2016).

At request of the UK Blood Services Forum, a study was performed to evaluate the available evidence on the safety of accepting blood donors beyond the age of 70. Evidence was obtained from demographic and blood service data, and an additional review of key literature was performed. Evidence showed that it is safe for regular donors of whole blood and blood components to continue donating beyond the age of 70, with no absolute upper limit, on condition that they meet the other acceptance criteria for blood donation.

Concerning the safety of the blood recipient, a systematic review on the safety and effectiveness of blood from uncomplicated hemochromatosis patients for blood transfusion stated that there was no evidence to suggest that blood from hemochromatosis patients without complications of iron overload is unsafe for transfusion. There was also no evidence that their blood would present a greater risk to the safety of the recipient than blood from healthy donors. However, two in vitro studies suggested that iron-overloaded patients might be more susceptible to bacterial growth, but these findings should be confirmed by in vivo studies. Also, harmonization of the blood donor selection policy among countries allowing hemochromatosis patients to donate blood once iron levels are normalized is needed.

In 2015, a systematic review was performed to investigate whether to investigate whether male blood donors, having sex with men, present a risk of TTIs in Western countries. Fifteen low-quality observational studies suggested a link between blood donors who were MSM and HIV-1 infection, but the evidence is too limited to recommend a precise deferral period.

Recently, a systematic review was performed on the risk of TTIs in blood donors who recently had an endoscopic examination, since the invasive procedure and the reusable character of an endoscope could threaten a safe blood supply. Twenty-eight observational studies (of very low quality) were included, and several meta-analyses showed an association between endoscopic examinations and hepatitis B and C infection. To take into account the differences in prevalence...
of these infections between European and African countries, a subanalysis was performed for European countries only, which still showed a significant association between endoscopic examinations and HBV and HCV infection (personal communication Centre for Evidence-Based Practice, Belgian Red Cross-Flanders, 2016).

**Primary research articles**

No high-quality studies were identified. A total of 43 low-quality observational studies were found. Table 2 shows the number of studies identified for each of the seven categories of donor deferral criteria. The identified studies either looked at risk factors for adverse events in the donor, or risk factors for possible transmission of infections such as HIV or hepatitis. Of these 43 studies, 27 performed a multivariate analysis (following univariate analysis). Here, we only mention risk factors which showed a significant association in the multivariate analysis.

For category I of the deferral criteria, considering conditions that may increase the risk of serious adverse reactions, a total of eight studies were identified. Of these, four studies found the following significant risk factors for adverse reactions in donors: low estimated blood volume, younger age, first-time donation, female sex, higher pulse rate, lower body mass index, and race.10,11,13,16

Eleven studies were identified that looked at conditions with proven transmissibility by transfusion (category IV). Of these, five studies found evidence showing that the following risk factors were significantly associated with transmission of infections: (history of) hepatitis, sexually transmitted diseases in males, and being HBV or HCV positive in males.21,23,24,27,48

Thirty-four studies were relevant for conditions including exposure to conditions with proven transmissibility by transfusion (category V), of which 21 performed a multivariate analysis. Significant risk factors identified in multiple studies were previous blood transfusion, (history of) injectable or intranasal drug use, tattoo, living in a closed institution (prison or juvenile detention), sex with a drug user, contact with blood from another person, body piercing, acupuncture, major or minor surgery, hospitalization, sexual promiscuity, MSM, and occupational exposure.10,20,21,23,24,27,28,31,32,34,37,38,41-46,48,49,51,52

Regarding conditions with possible or unknown transmissibility by transfusion (category VI), three studies were identified. However, none of these studies performed multivariate statistical analyses. Univariate analysis showed that jaundice and elevated alanine aminotransferase are significant risk factors for infections.26,36

No studies were identified for category II (conditions that may interfere with the feasibility of the donation procedure), category III (conditions that may affect the quality of blood products), and category VII (conditions including exposure to conditions with possible or unknown transmissibility by transfusion) of the deferral criteria.

**Health technology assessments**

Three cost-effectiveness analyses concerning blood donor exclusion criteria were identified (Table 2). In the first study, the cost-effectiveness of the entire medical questionnaire (currently used in the Netherlands, ie, the Donor Health Questionnaire) was investigated. It was found that the incremental cost-effectiveness ratio for the Donor Health Questionnaire (including costs for deferred donors) on preventing TTIs was €1,449,005 (95% confidence interval: €669,439–€3,145,961).
Hence, it was concluded that this medical questionnaire is not a cost-effective tool to further reduce TTIs, although its role in self-selection precludes abandoning the medical questionnaire. In the second study, the cost-effectiveness of using a medical questionnaire followed by PCR testing specifically for malaria was estimated via a decision analysis model. Compared to not using a medical questionnaire, the incremental cost-effectiveness ratio was $6,463 per case of malaria averted when using the medical questionnaire followed by PCR. A third analysis was a cost-benefit analysis with an implicit valuation of Israel’s decision (in 1990s) to exclude blood donations from Ethiopian immigrants, due to the high prevalence of HIV infection in this community relative to the rest of the Israeli population. This analysis demonstrated that this exclusion policy could not be considered as justifiable on public health grounds if the annual social exclusion costs exceed $218,000 per year or $3.63 per Ethiopian immigrant.

Another form of cost is the impact of temporary deferral on donor retention with the subsequent need to attract new donors. Several studies have demonstrated that even short-term deferral may have a significant impact on the return rate. In our own donor population, 42% of temporarily deferred donors – all reasons – in 2012 did not return within a 3-year period after donation as compared to 30% of eligible donors.

**HTA papers on all blood-banking safety measures currently used**

Thirteen cost-utility analyses, conducted in five Western, developed countries, were retained (Table 3). The HCV/HIV antibody testing, compared to no testing, was the only cost-effective (ie, cost-saving) intervention, whereas the cost/QALY for the other interventions all exceeded the cost-effectiveness threshold. Indeed, the World Health Organization indicated that the cost-effectiveness threshold would be three times the gross domestic product per head. For the included Western countries, this threshold ranges between €90,000/QALY and €120,000/QALY.

**Reasons for donor exclusion**

The top 30 reasons for excluding candidate donors who present themselves for donation in Flanders (Belgium) cover 90% of all exclusions, and are detailed in Table 4. Low hemoglobin levels constitute >40% of all deferrals.

When comparing Table 4 with the evidence available on donor deferral criteria (Table 2), we can conclude that for 60% of the top 30 reasons for donor deferral, no evidence is available. For 40% of the top 30 deferral reasons, only low quality evidence is available.

**Discussion**

Blood products are lifesaving. During donor selection, different deferral criteria are used. These criteria are based on the precautionary principle to protect safety and quality, on supply considerations to ensure access, and on expense considerations. This model has served the patients well: it provided adequate quantities of safe blood at a reasonable price.

The precautionary principle is increasingly criticized, mainly for not taking into account donor preference. Alternatives to the precautionary principle, however, always make the decision-making process more complex, and sometimes also more expensive, and hence require more and more sophisticated scientific data, and may require higher reimbursement.

This review provides an overview of (1) the available evidence base for donor exclusion criteria applied to the most common reasons of deferral at our Blood Service (Table 4), and (2) the available evidence on cost-effectiveness for blood-banking safety interventions. Given the many different reasons for donor exclusion (30 different reasons explain 90% of all exclusions), many gaps exist today in the scientific evidence: only seven systematic reviews concerning blood donor selection criteria were available, only 43 papers were found containing primary research (none of high quality), and with regard to cost effectiveness, again only three papers were found. For 60% of the top 30 deferral reasons no evidence was available, and whatever evidence was available for the remaining deferral reasons was of low quality.

The scarcity of scientific data is not surprising: if one accepts the precautionary principle as has been the case for many years, precise data are not essential to take safety measures.

The ramifications of replacing or eliminating the precautionary principle in favor of a shift to an evidence-based approach are significant. The classic triad of evidence-based work consists of the best available scientific evidence, complemented by expert opinion and by the preferences of the target population (in this case both patients and donors). In the absence of unambiguous and strong evidence, as is the case here, expert opinion and target population preference play a bigger role than if stronger quality evidence were available.

The evidence-based process can be illustrated using MSM as an example. Preference of donors is clear: they perceive...
exclusion to be discriminatory and would like to be able to donate blood.\textsuperscript{73} Preference of the patient population is also clear: they expect to receive the safest blood possible. Experts mostly favor exclusion of MSM due to the following reasons: 1) they take into account low-quality evidence such as extrapolations from infectious disease incidence in MSM groups, often extrapolating on data from outside the field of transfusion medicine, and there is much circumstantial evidence to support an increased risk of HIV and other sexually transmitted diseases in at least a subpopulation of gays; 2) the risk of transmission of infectious diseases, not tested for or which are (as yet) unknown, is also higher in this population;\textsuperscript{75,76} 3) laboratory tests cannot guarantee total safety (a recent study reported an error rate of 0.01% of third- and fourth-generation HIV tests);\textsuperscript{77} and 4) the instinct and tradition of the sector experts is to make blood safer, with zero risk as the ultimate goal.\textsuperscript{78,79} This is partly the result of the AIDS epidemic of the early 1980s which led to the infection of thousands of people after receiving a blood transfusion or blood products before HIV antibody testing became available. Although this situation is not comparable to the current scientific and health climate, the scare (and medicolegal consequences) of that episode still resides in many minds. As long as stronger evidence as to safety in case of MSM is not available, the precautionary principle still is valid to ensure the safety of the blood supply. However, many jurisdictions have sought to reexamine their policy on deferral of MSM guided by model-based analysis and not based on evidence.\textsuperscript{80} Replacing the precautionary principle by an evidence-based approach would thus imply certain challenges. If we do not want to replace the precautionary principle

### Table 3 Cost/QALY of safety measures used in the blood-banking sector

| Intervention | Comparison | Country     | Cost/QALY* | References |
|--------------|------------|-------------|------------|------------|
| Medical questionnaire (donor health questionnaire) → prevention of HIV/HBV/HCV | No medical questionnaire | the Netherlands | 696,744 (315,422–1,611,681) | de Kort et al\textsuperscript{17} |
| **Laboratory testing** | | | | |
| Individual-donor NAT + serologic tests (HBV/HCV/HIV) | Serologic tests | Sweden | 3,726,637 | Davidson et al\textsuperscript{63} |
| Triplex NAT (HBV/HCV/HIV) + serologic tests | Serologic tests | the Netherlands | 5,200,000 | Borkent-Raven et al\textsuperscript{64} |
| Minipool NAT (HBV/HCV/HIV) + serologic tests | Serologic tests | USA | 2,055,000 (1,370,000–2,877,000) | Marshall et al\textsuperscript{65} |
| Individual NAT (HBV/HCV/HIV) + serologic tests | Serologic tests | USA | 2,507,100 | Janssen et al\textsuperscript{66} |
| HIV antibody | No test | the Netherlands | 124,254 (24,864–2,861,729) | Bell et al\textsuperscript{11} |
| HIV antibody | HIV antibody | | 2,693,420 | \textsuperscript{[4]} |
| HCV antibody | No screening | | Cost saving | \textsuperscript{4932} |
| HCV antibody | Antibody | Spain | 2,507,100 | Pereira et al\textsuperscript{69} |
| Bacterial testing | Antibody | the Netherlands | 124,254 (24,864–2,861,729) | Janssen et al\textsuperscript{70} |
| **Platelet preparation** | | | | |
| Pathogen reduction technology (Intercept) + single-donor apheresis platelets (without bacterial testing) | Untreated single-donor apheresis platelets | USA | Range: 1,793,101–6,098,760 | Bell et al\textsuperscript{71} |
| Pathogen reduction technology (Intercept) + single-donor apheresis platelets (with bacterial testing) | Untreated single-donor apheresis platelets | | Range: 6,520,379–31,466,250 | Bell et al\textsuperscript{71} |
| Pathogen reduction technology (Intercept) + random-donor pooled platelet concentrations | Untreated random-donor pooled platelet concentrations | USA | 626,892–2,488,002 | Bell et al\textsuperscript{71} |
| Pathogen reduction technology (Mirasol) | Current screens and interventions | | 1,748,000 (822,000–4,538,810) | Custer et al\textsuperscript{72} |
| Pathogen reduction technology (type of technology: not reported) | No pathogen reduction technology | the Netherlands | 680,443 (197,211–11,194,452) | Janssen et al\textsuperscript{70} |
| Pathogen reduction technology (Intercept) | No pathogen reduction technology | Belgium | Range: 267,648–4,739,105 | Moeremans et al\textsuperscript{73} |

**Notes:** \textsuperscript{*}Costs are presented in €. Costs were converted from $USD to € (1€=1.37$) if needed. Data is presented as mean (95% CI), unless otherwise indicated. 

**Abbreviations:** QALY, quality-adjusted life-years; CI, confidence interval; HBV, hepatitis B virus; HCV, hepatitis C virus; NAT, nucleic acid test.
(based on science, be it on weak evidence) by a mere clash of preferences (in which advocacy determines the outcome in the absence of any scientific evidence), more and better primary research and evidence-based analyses are needed.

In the meantime, policy makers should make choices at the level of general principles: whether more emphasis should be placed on donor or on patient issues (safety, preferences, etc), that is, striking the right balance between the right to donate blood versus the right to receive the safest blood possible. Selective interference at a technical level is to be avoided because mandating exceptions to the precautionary principle challenges the principle without understanding all consequences.

Furthermore, policy makers should define the right balance not only between the rights of patients and donors but also between costs and benefits of donor deferral measures. Policy decisions that replace cheap safety measures (such as the medical questionnaire) by more expensive measures (such as laboratory tests) push up the price for blood products, in a sector that already accepts exceptionally high cost-effectiveness levels. Table 3 documents the unique position of blood banking in the health care landscape. Many measures taken in the field of blood banking cost much more than the normally accepted €50,000/QAL Y limit. Second-generation HIV tests, for example, are estimated to cost nearly $2.7 million/QAL Y. And estimates for pathogen inactivation of platelets even go as high as a mind-boggling €31 million/QAL Y (yet it gets introduced in many health care systems without much discussion, sometimes on the basis of one highly mediatized infection in the country). Cost/QAL Y could

Table 4 Top 30 reasons of donor exclusion in Belgium

| Reason for donor exclusion | Category of deferral | % of total number of exclusions | Evidence available? |
|----------------------------|----------------------|---------------------------------|---------------------|
| Low hemoglobin levels      | I                    | 41.82%                          | No                  |
| Asymptomatic visitor of an area outside Europe (Recommendation of the Belgian Superior Health Council) | V | 6.82% | No |
| New sexual partner         | V                    | 6.75%                           | Low quality         |
| Asymptomatic visitor to a malaria endemic area | V | 4.76% | No |
| Non-specified infectious diseases | VI | 4.50% | No |
| Dental treatment           | V                    | 4.09%                           | No                  |
| Endoscopic examination using flexible instruments | V | 3.58% | Low quality |
| Minor surgery              | V                    | 3.16%                           | Low quality         |
| Percutaneous needle contact (tattoo, body piercing, acupuncture) by a non-qualified practitioner | V | 3.11% | Low quality |
| Specific infectious diseases (other than viral hepatitis, sexually transmitted diseases) | VI | 2.66% | No |
| Pregnancy                  | I                    | 2.16%                           | No                  |
| High blood pressure        | I                    | 1.88%                           | Low quality         |
| Serious cardiovascular disease | I | 1.62% | No |
| Low blood pressure         | I                    | 1.47%                           | Low quality         |
| Asymptomatic visitor of an area with ongoing transmission of West Nile Virus to humans | V | 1.22% | No |
| Malignant disease          | VI                   | 1.20%                           | No                  |
| Short interdonation interval | I | 1.16% | No |
| Endoscopic examination using rigid instruments | V | 1.11% | Low quality |
| Medication (with possible side effect for the recipient) | VI | 0.98% | No |
| Major surgery              | V                    | 0.82%                           | Low quality         |
| Body weight <50 kg         | I                    | 0.72%                           | Low quality         |
| Tick bite (Lyme disease)   | VII                  | 0.65%                           | No                  |
| Serious hematological disease | I, III | 0.65% | Low quality |
| Serious central nervous system disease | VI | 0.63% | No |
| Hepatitis B vaccine        | II                   | 0.58%                           | No                  |
| Sexual risk behavior with temporary deferral | V | 0.45% | Low quality |
| Bariatric surgery          | I                    | 0.43%                           | No                  |
| Chronic inflammatory diseases | VI | 0.36% | No |
| Serious musculoskeletal system diseases | VI | 0.32% | No |
| Mucosal splash or needle stick injury | V | 0.32% | Low quality |
drop should pathogen inactivation lead to the elimination of other safety measures such as diagnostic tests, less stringent donor selection criteria, or when confronted with the outbreak of (new) epidemics for which no diagnostic tests (yet) exist or diagnostic tests are too expensive, just as cost/QALY might increase even further if lower corrected count increment results in shorter transfusion intervals or higher platelet doses, if the number of patients with platelet refractoriness increases or if in vitro-observed reduction in thrombus formation kinetics translates to increased bleeding risk in patients.

However, despite the current high costs of blood transfusion, it remains an essentially cheap modality, compared to alternative interventions such as the use of erythropoietin-stimulating agents (ESAs). A recent systematic review compared the cost/QALY of these ESAs with red blood cell transfusion, showing that red blood cell transfusion is still more cost-effective than the use of ESAs.

Despite the high cost/QALY, patients are willing to pay substantial amounts for safe blood products for transfusion. The reasons why the willingness to pay in the blood-banking sector is so high probably include several elements. On the one hand, blood seems to be a more emotional issue with a broader public, than most other health care and certainly non-health care issues. Whether this is due to the fact that blood has a symbolic value throughout history, representing life, not only in medicine but also in arts, is a possibility. On the other hand, deferral criteria are mainly regulated by legislation which can be influenced by elected politicians. Furthermore, the use of recovered plasma for fractionation is sometimes complicated by the fact that plasma-derived products typically fall under pharmaceutical legislation, for which an international market exists, whereas donor criteria for whole-blood donation typically are governed country by country.

Whatever the reasons, blindly implementing the generally accepted cost/QALY cut-off of the health care sector would have drastic consequences. If we accept a limit similar to what is applied and accepted in other fields of medicine (€50,000/QALY), many if not most measures that are routinely in use in most developed blood-banking systems would be eliminated. Whether anyone, either policy maker or blood bank professional, is willing to take responsibility for making this shift is doubtful. Acceptance for risk indeed seems to be lower when it comes to blood banking than in other areas of health care.

All in all, replacing the precautionary principle by a more evidence-based approach sounds evident but is not possible in the short term due to lack of scientific evidence. Fortunately, a tool to help streamline this process has recently been developed, defining a risk-based approach to blood-banking safety measures.

Conclusion
Blood products save the lives of millions of people worldwide. The historical model based on the precautionary principle and on supply and expense considerations provided adequate supplies of safe blood at a reasonable price. This model is increasingly being challenged. However, it is clear that more and better primary research and evidence-based analyses are required to be able to replace this model by an evidence-based approach. In the meantime, policy makers should provide guidance at the level of principles, not at the level of technical measures, about the balance between patient and donor rights, and about the acceptable cost-effectiveness implications of these choices.

Acknowledgment
Belgian Red Cross-Flanders is responsible for supplying adequate quantities of safe blood products to hospitals in Flanders and Brussels.

Disclosure
The authors report no conflicts of interest in this work.

References
1. World Health Organization. Blood Donor Selection: Guidelines on Assessing Donor Suitability for Blood Donation. Geneva: World Health Organization; 2012.
2. Vandewalle G, Compernolle V, Vandekerckhove P. A comprehensible approach toward donor selection guidelines in Europe. 2014.
3. De Kort W, Mayr W, Junghauer C, et al. Blood donor selection in European Union directives: room for improvement. Blood Transfus. 2016;14(2):101–108.
4. United Kingdom Blood Services. Handbook of Transfusion Medicine. 5th ed. Norfolk D, editor. Sheffield: TSO; 2013.
5. American Red Cross. In-depth discussion of variant Creutzfeld-Jacob disease and blood donation. 2016. Available from: http://www.redcrossblood.org/donating-blood/eligibility-requirements/eligibility-criteria-alphabetical-listing. Accessed on January 27, 2016.
6. Pauwels NS, Cusack L, De BE, Compernolle V, Vandekerckhove P. The effect of pre-donation hypotension on whole blood donor adverse reactions: a systematic review. J Am Soc Hypertens. 2014;8(6):429–436.
7. Stainsby D, Brunskill S, Chapman CE, Doree C, Stanworth S. Safety of blood donation from individuals with treated hypertension or non-insulin dependent type 2 diabetes—a systematic review. Vox Sang. 2010;98 (3 Pt 2):431–440.
8. Stainsby D, Butler M. Recommendations for the Removal of the Upper Age Limit for Regular Whole Blood and Component Donors. Joint United Kingdom (UK) Blood Transfusion and Tissue Transplantation Services Professional Advisory Committee; 2008.
9. Callahan R, Edelman EB, Smith MS, Smith JJ. Study of the incidence and characteristics of blood donor “reactors”. Transfusion. 1963;3:76–82.
10. Gillet P, Rapaille A, Benoit A, et al. First-time whole blood donation: a critical step for donor safety and retention on first three donations. *Transfus Clin Biol*. 2015;22(5–6):312–317.

11. Goldman M, Osmond L, Yi QL, Cameron-Choi K, O’Brien SF. Frequency and risk factors for donor reactions in an anonymous blood donor survey. *Transfusion*. 2013;53(9):1979–1984.

12. Kasprisin DO, Glyn SH, Taylor F, Miller KA. Moderate and severe reactions in blood donors. *Transfusion*. 1992;32(1):23–26.

13. Takashita M, Odajima T, Aota S, et al. Risk factor analysis of vasovagal reaction from blood donation. *Transfusion Apher Sci*. 2012;47(3):319–325.

14. Tomaszko PA, Anderson AJ, Paluso MB. A study of criteria for blood donor deferral. *Transfusion*. 1980;20(5):511–518.

15. Trouen-Trend JJ, Cable RG, Baidon SJ, Newman BH, Popovsky MA. A cost-controlled multicenter study of vasovagal reactions in blood donors: influence of sex, age, donation status, weight, blood pressure, and pulse. *Transfusion*. 1999;39(3):316–320.

16. Wiltbank TB, Giordano GF, Kamel H, Tomaszko P, Custer B. Faint reactions and prefaint reactions in whole-blood donors: an analysis of pre-donation measurements and their predictive value. *Transfusion*. 2008;48(9):1799–1808.

17. de Kort W, van den Burg P, Geerligs H, Pasker-de Jong MJ, Marijt-van der Kreek T. Cost-effectiveness of questionnaires in preventing transfusion-transmitted infections. *Transfusion*. 2014;54(3 Pt 2):879–888.

18. De Buck E, Pauwels NS, Deltjens T, Compernolle V, Vandekerckhove P. Is blood of uncomplicated hemochromatosis patients safe and effective for blood donation? A systematic review. *J Hepatol*. 2012;57(5):1126–1134.

19. Cardoso MD, Koerner K, Dengler T, Kubanek B. Identification of infection routes for HCV in blood donors from Germany. *Infusionsther Transfusionsmed*. 1998;25(6):370–372.

20. Conry-Cantilena C, VanRaden M, Gibble S, et al. Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. *N Engl J Med*. 1996;334(26):1691–1696.

21. Esteban JI, Lopez-Talaver JC, Genesca J, et al. High rate of infection and liver disease in blood donors with antibodies to hepatitis C virus. *Ann Intern Med*. 1991;115(5):443–449.

22. Murphy EL, Bryzman SM, Glynn SA, et al. Risk factors for hepatitis C virus (HCV) infection in US blood donors—lack of association with drug inhalation. *Transfusion*. 1998;38(10):735–741.

23. Neil KR, Jones DA, Killey D, James V. Risk factors for hepatitis C virus infection. A case-control study of blood donors in the Trent Region (UK). *Epidemiol Infect*. 1994;112(3):595–601.

24. Neto CA, Sabino EC, Chen S, McFarland W, Murphy EL. Analysis of HIV seropositive blood donors risk factors—a way to improve blood donor screening. *Transfusion*. 2005;45(3):98A.

25. Orton SL, Stramer SL, Dodd RY, Alter MJ. Risk factors for HCV infection among blood donors confirmed to be positive for the presence of HCV RNA and not reactive for the presence of anti-HCV. *Transfusion*. 2004;44(2):275–281.

26. Serfaty L, Glyn SH, Taylor F, Miller KA. Moderate and severe reactions in blood donors. *Transfusion*. 1992;32(1):23–26.

27. Shev S, Hermodsson S, Lindholm A, Malm E, Widdel A, Norkrans G. Risk factor exposure among hepatitis C virus RNA positive Swedish blood donors—the role of parental and sexual transmission. *Scand J Infect Dis*. 1995;27(2):99–104.

28. Vickers K, Tawk HM, Bissel L, Selby W, Cossart YE. Hepatitis C virus infection rates and risk factors in an Australian hospital endoscopy cohort. *Aust N Z J Public Health*. 2009;33(5):442–448.

29. Zou S, Fujii K, Johnson S, et al. Prevalence of selected viral infections among blood donors deferred for potential risk to blood safety. *Transfusion*. 2006;46(11):1997–2003.

30. Shehata N, Kohli M, Detsky A. The cost-effectiveness of screening blood donors for malaria by PCR. *Transfusion*. 2004;44(2):217–228.
51. O'Brien SF, Fan W, Xi G, et al. Declining hepatitis C rates in first-time blood donors: insight from surveillance and case-control risk factor studies. *Transfusion*. 2008;48(8):902–909.

52. Schreiber GB, Murphy EL, Horton JA, et al. Risk factors for human T-cell lymphotropic virus types I and II (HTLV-I and -II) in blood donors: the Retrovirus Epidemiology Donor Study. *NHLBI Retrovirus Epidemiology Donor Study. J Acquir Immune Defic Syndr Hum Retrovirol*. 1997;14(3):263–271.

53. Soresi M, Mazzola A, Carroccio A, et al. Transmission of hepatitis C virus: a study of the main risk factors in a Sicilian population of volunteer blood donors. *Hepatogastroenterology*. 1998;45(19):150–153.

54. van der Poel C, Cuypers H, Reesink H, et al. Risk factors in hepatitis C virus-infected blood donors. *Transfusion*. 1991;31(8):777–779.

55. Wong P-Y, Dodd R, Kiely P, Whyte G. Characteristics of hepatitis C-positive blood donors in Victoria, Australia. *Transfus Med*. 1999;9(1):15–19.

56. Kaplan EH. Implicit valuation of a blood-exclusion decision. *Med Decis Making*. 1999;19(2):207–213.

57. Custer B, Schumpef KS, Wright D, Simon TL, Wilkinson S, Ness PM. Risk factor for human immunodeficiency antibody: cost-benefit analysis. *Vox Sang*. 1988;78(4):450–454.

58. Custer B, Schlumpf KS, Wright D, Simon TL, Wilkinson S, Ness PM. Risk factor for human immunodeficiency virus among blood donors: the Retrovirus Epidemiology Donor Study. *Transfusion*. 2007;47(8):1514–1523.

59. Kaplan EH. Implicit valuation of a blood-exclusion decision. *Med Decis Making*. 1999;19(2):207–213.

60. Custer B, Chinn A, Hirschler NV, Busch MP, Murphy EL. The consequences of temporary deferral on future whole blood donation. *Transfusion*. 2007;47(8):1514–1523.

61. Schreiber GB. Declining value of alanine aminotransferase in screening for hepatitis C virus: a study of the main risk factors in a Sicilian population of volunteer blood donors. *Hepatogastroenterology*. 1998;45(19):150–153.

62. WHO. Cost effectiveness and strategic planning (WHO-CHOICE). Geneva: World Health Organization; 2001.

63. Davidson T, Ekermo B, Gaines H, Lesko B, Akerlind B. The cost-effectiveness of introducing nucleic acid testing to test for hepatitis B, hepatitis C, and human immunodeficiency virus among blood donors. *Transfusion*. 2011;51(6):1188–1196.

64. Hillgrove T, Moore V, Doherty K, Ryan P. The impact of temporary deferral due to low hemoglobin: future return, time to return, and frequency of subsequent donation. *Transfusion*. 2011;51(3):539–547.

65. Zou S, Musavi F, Notari EP, Rios JA, Trounson-Trend J, Fang CT. Donor deferral and resulting donor loss at the American Red Cross Blood Services, 2001 through 2006. *Transfusion*. 2008;48(12):2531–2539.

66. Sachs J. *Macroeconomics and Health: Investing in Health for Economic Development*. Geneva: World Health Organization; 2001.

67. WHO. Cost effectiveness and strategic planning (WHO-CHOICE). 2016. Available from: http://www.who.int/choice/cost-effectiveness/en/. Accessed on January 27, 2016.

68. Davidon T, Ekermo B, Gaines H, Lesko B, Akerlind B. The cost-effectiveness of introducing nucleic acid testing to test for hepatitis B, hepatitis C, and human immunodeficiency virus among blood donors in Sweden. *Transfusion*. 2011;51(2):421–429.

69. Borkent-Raven BA, Janssen MP, van der Poel CL, Bonsel GJ, van Hout BA. Cost-effectiveness of additional blood screening tests in the Netherlands. *Transfusion*. 2012;52(3):478–488.

70. Marshall DA, Kleinman SH, Wong JB, et al. Cost-effectiveness of nucleic acid test screening of volunteer blood donors for hepatitis B, hepatitis C, and human immunodeficiency virus in the United States. *Vox Sang*. 2004;86(1):28–40.

71. Eisenstaedt RS, Getzen TE. Screening blood donors for human immunodeficiency virus antibody: cost-benefit analysis. *Am J Public Health*. 1988;78(4):450–454.

72. Aubuchon JP. Cost-effectiveness of preoperative autologous blood donation for orthopedic and cardiac surgeries. *Am J Med*. 1996;101(2A):385–425.

73. Busch MP, Korelitz JJ, Kleinman SH, Lee SR, Aubuchon JP, Schreiber GB. Declining value of alanine aminotransferase in screening of donors to prevent posttransfusion hepatitis B and C virus infection. The Retrovirus Epidemiology Donor Study. *Transfusion*. 1995;35(11):903–910.

74. Pereira A, Sanz C. A model of the health and economic impact of posttransfusion hepatitis C: application to cost-effectiveness analysis of further expansion of HCV screening protocols. *Transfusion*. 2000;40(10):1182–1191.

75. Janssen MP, van der Poel CL, Buskens E, Bonneux L, Bonsel GJ, van Hout BA. Costs and benefits of bacterial culturing and pathogen reduction in the Netherlands. *Transfusion*. 2006;46(6):956–965.

76. Bell CE, Botteman MF, Gao X, et al. Cost-effectiveness of transfusion of platelet components prepared with pathogen inactivation treatment in the United States. *Clin Ther*. 2003;25(9):2464–2486.

77. Custer B, Agapova M, Martinez RH. The cost-effectiveness of pathogen reduction technology as assessed using a multiple risk reduction model. *Transfusion*. 2010;50(11):2461–2473.

78. Moeremans K, Waric H, Annemans L. Assessment of the economic value of the INTERCEPT blood system in Belgium. *Transfus Med*. 2006;16(1):17–30.

79. Roehr B. Should men who have ever had sex with men be allowed to give blood? Yes. *BMJ*. 2009;338:b311.

80. Friedman MR, Wei C, Klem ML, Silvestre AJ, Markovic N, Stall R. HIV infection and sexual risk among men who have sex with men and women (MSMW): a systematic review and meta-analysis. *PLoS One*. 2014;9(1):e87139.

81. Butler C, Doree C, Estcourt LJ, et al. Pathogen-reduced platelets for the prevention of bleeding. *Transfus Med Rev*. 2014;28(4):215–224.

82. Reis W, Tsyshko M, Krewski D. Men having sex with men donor deferral risk assessment: an analysis using risk management principles. *Transfus Med Rev*. 2008;22(1):35–57.

83. Menitove JE, Leach BJ, Tomasulo P, Katz LM. How safe is safe enough, who decides and how? From a zero-risk paradigm to risk-based decision making. *Transfusion*. 2014;54(3 Pt 2):753–757.

84. Custer B, Shen N, Sieddie-Khan B, et al. Blood donor deferral for men who have sex with men: the Blood Donation Rules Opinion Study (Blood DROPS). *Transfusion*. 2015;55(12):2826–2834.

85. Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness—the curious resilience of the $50,000-per-QALY threshold. *N Engl J Med*. 2014;371(9):796–797.

86. Butler C, Doree C, Estcourt LJ, et al. Pathogen-reduced platelets for the prevention of bleeding. *Cochrane Database Syst Rev*. 2013;3:CD009072.

87. Van Aelst B, Feys HB, Davloof R, Vanhoorelbeke K, Vandekerckhove P, Compernolle V. Riboflavin and amotosalen photochemical treatments of platelet concentrates reduce thrombus formation kinetics in vitro. *Vox Sang*. 2015;108(4):328–339.

88. Ferguson T, Xu Y, Gunasekara R, et al. The cost effectiveness of erythropoietin-stimulating agents for treating anemia in patients on dialysis: a systematic review. *Am J Nephrol*. 2015;41(2):89–97.

89. Lee SJ, Neumann PJ, Churchill WH, Cannon ME, Weinstein MC, Johannesson M. Patients’ willingness to pay for autologous blood donation. *Health Policy*. 1997;40(1):1–12.

90. Lee SJ, Liljas B, Churchill WH, et al. Perceptions and preferences of autologous blood donors. *Transfusion*. 1998;38(8):757–763.

91. Moxey AJ, O’Connell DL, Treloar CJ, Han PY, Henry DA. Blood transfusion and autologous donation: a survey of post-surgical patients, interest group members and the public. *Transfus Med*. 2005;15(1):19–32.
